PACB — Pacific Biosciences Of California Share Price
0.000.00%
Last trade - 00:00- $849.41m
- $1.11bn
- $200.52m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.21 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 4.24 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -20.38% | ||
| Return on Equity | -48.53% | ||
| Operating Margin | -167.81% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 90.89 | 78.89 | 130.51 | 128.3 | 200.52 | 238.67 | 346.94 | 20.59% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Pacific Biosciences of California, Inc. is a life science technology company. It is engaged in designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to resolve genetically complex problems. Its products and technology under development stem from two differentiated core technologies, which include its HiFi long-read sequencing technology and its Sequencing by Binding (SBB) short-read sequencing technology. Its products address solutions across a set of applications, including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. It has developed HiFi long-read sequencing based on Single-Molecule Real-Time technology, which accurately detects the nucleotide sequence and epigenetic status of individual DNA molecules. Its Revio, Sequel, Sequel II and Sequel IIe instruments conduct, monitor, and analyze single-molecule biochemical reactions in real time.
Directors
- John Milligan CHM (60)
- Christian Henry PRE (53)
- Susan Kim CFO (45)
- Mark Van Oene COO (48)
- Catherine Ball SVP
- Denis Zaccarin SVP (56)
- Michele Farmer CAO
- Peter Fromen OTH (46)
- Kathy Ordonez DRC (70)
- David Botstein IND (78)
- William Ericson IND (62)
- Randall Livingston IND (67)
- Marshall Mohr IND (65)
- Lucy Shapiro IND (80)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- July 14th, 2000
- Public Since
- October 27th, 2010
- No. of Shareholders
- 76
- No. of Employees
- 796
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 267,951,880
- Address
- 1305 O'brien Drive, MENLO PARK, 94025
- Web
- https://www.pacb.com/
- Phone
- +1 6505218000
- Auditors
- Ernst & Young LLP
Upcoming Events for PACB
Pacific Biosciences of California Inc Annual Shareholders Meeting
Q2 2024 Pacific Biosciences of California Inc Earnings Release
Similar to PACB
10X Genomics
NASDAQ Global Select Market
Accuray
NASDAQ Global Select Market
Akoya Biosciences
NASDAQ Global Select Market
Align Technology
NASDAQ Global Select Market
Alphatec Holdings
NASDAQ Global Select Market
FAQ
What is the Pacific Biosciences Of California share price?
As of Today at 19:16 UTC, shares in Pacific Biosciences Of California are trading at $3.17. This share price information is delayed by 15 minutes.
How has the Pacific Biosciences Of California share price performed this year?
Shares in Pacific Biosciences Of California last closed at $3.17 and the price had moved by -72.41% over the past 365 days. In terms of relative price strength the Pacific Biosciences Of California share price has underperformed the S&P500 Index by -77.72% over the past year.
What are the analyst and broker recommendations for Pacific Biosciences Of California?
The overall consensus recommendation for Pacific Biosciences Of California is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Pacific Biosciences Of California dividend yield?
Pacific Biosciences Of California does not currently pay a dividend.
Does Pacific Biosciences Of California pay a dividend?
Pacific Biosciences Of California does not currently pay a dividend.
When does Pacific Biosciences Of California next pay dividends?
Pacific Biosciences Of California does not currently pay a dividend.
How do I buy Pacific Biosciences Of California shares?
To buy shares in Pacific Biosciences Of California you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Pacific Biosciences Of California?
As of the previous close price of $3.17, shares in Pacific Biosciences Of California had a market capitalisation of $849.41m.
Where are Pacific Biosciences Of California shares listed?
Here are the trading details for Pacific Biosciences Of California:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: PACB
What kind of share is Pacific Biosciences Of California?
Based on an overall assessment of its quality, value and momentum Pacific Biosciences Of California is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Pacific Biosciences Of California share price forecast for 2024?
The analyst consensus target price for shares in Pacific Biosciences Of California is $10.21. That is 222.08% above the last closing price of $3.17.
Analysts covering Pacific Biosciences Of California currently have a consensus Earnings Per Share (EPS) forecast of -$1.03 for the next financial year.
What is the trend in the Pacific Biosciences Of California share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Pacific Biosciences Of California. Over the past six months, its share price has underperformed the S&P500 Index by -66.09%.
As of the last closing price of $3.17, shares in Pacific Biosciences Of California were trading -61.94% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Pacific Biosciences Of California PE Ratio?
The Pacific Biosciences Of California PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $3.17.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Pacific Biosciences Of California?
Pacific Biosciences Of California's management team is headed by:
- John Milligan - CHM
- Christian Henry - PRE
- Susan Kim - CFO
- Mark Van Oene - COO
- Catherine Ball - SVP
- Denis Zaccarin - SVP
- Michele Farmer - CAO
- Peter Fromen - OTH
- Kathy Ordonez - DRC
- David Botstein - IND
- William Ericson - IND
- Randall Livingston - IND
- Marshall Mohr - IND
- Lucy Shapiro - IND